Top Articles

Registration for the 6th EAN Congress in Paris, France, 23 May-26 May 2020, is now possible!

The  Portuguese Neurological Society has submitted its guidelines, which are now available for EAN Members in the Guideline Reference Center.

Production of European standards of diagnosis, treatment and care within the various subfields of neurology, is one of the most important aims of EAN. EAN has therefore set-up a Guideline Production Group (GPG), to provide scientific assistance to active task forces and to oversee the work flow.

As a follow-up to the survey on the renovation of the ICH Good Clinical Practice Guidelines (ICH E6) conducted in August, the Clinical Trials Transformation Initiative (CTTI) has launched a new open comment opportunity which enables specific comments to be collected.

Online voting for the EAN Scientific Panel Management Group members will begin on 8 October and continue through to 22 October.

Application for 2020 is open from 1 August until 31 October 2019

The Scientific Committee is fully committed to a great mission: To increase and share the best clinical knowledge and the cutting-edge information from translational research in all neurological fields. Main actions are i) to facilitate exchanges and synergies with the Scientific Panels ii) to support the Guideline Production Group (update and diffusion of expertise and best clinical practice), iii) to interact positively with other scientific societies with reciprocal exchanges and liaise with the European Affairs sub-Committee to increase the awareness of Neurology in Europe.

The next examination of the European Board of Neurology (EBN) will take place on Friday, 22 May 2020 at the EAN Congress in Paris.

Here are the first thress reports from those who took part in the EAN clincial Fellowships in 2019. Keep visitng EANpages over the next months to read more reports from other particpants from 2019.

I am happy to share with you that Prof. Franz Fazekas’s health has greatly improved.  We are in regular contact with him and his wife and expect (and wish) further recovery. Unfortunately, his current condition does not allow him to resume his function as President of our Society. As a consequence, the board has decided to ask me to take over his duties from September 1, 2019. To support the board and in accord with our bylaws, Prof. D. Vodusek, who already served in the EAN board, was appointed as member at large (until the next elections in Paris). I am very thankful to the entire board, the office, and particularly to Prof. G. Deuschl for their trust, support and advice in this delicate transition period.

Founded in1996, the European Institute of Women’s Health (EIWH) is a non-governmental organisation (NGO) and registered charity. The Institute uses an evidence-based approach to advocate for equitable, sex- and gender-sensitivity in health policy, research, promotion, treatment and care.  It also promotes biomedical and socio-economic research that addresses sex and gender-based differences to ensure access to quality treatment and care for women across their lifespan. 

For September 2019, we have selected two scientific papers with a common theme: Goadsby et al., Trial of galcanezumab in prevention of episodic cluster headache NEJM 2019; 381: 132-41, and Lipton et al., Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine NEJM 2019; 381: 142-9.

Switzerland is a beautiful country in the heart of Europe, stretching east to west from the lake of Constance to the lake of Geneva, and north to south from the river Rhine to the lago maggiore. Switzerland encompasses wonderful sceneries in the Alps, the middle lands and the Jura, which offer all kinds of outdoor activities in summer and winter, but also countless cultural events in his small but also metropolitan cities. Switzerland is a successful example that a multilingual and multicultural country can work. German, French, Italian and Roman are the national languages, and, with a population of 8.42 million inhabitants, Switzerland hosts more than 25% of foreign inhabitants from all over the world, all contributing to a beautiful, colorful and multicultural country, which regardless is deep-rooted in his traditions of independence, liberty, and direct democracy.

The European Medicines Agency has recommended that the multiple sclerosis medicine Gilenya (fingolimod) must not be used in pregnant women and in women able to have children who are not using effective contraception. If a woman becomes pregnant while using Gilenya, the medicine must be stopped and the pregnancy will have to be closely monitored. This is because the active substance in Gilenya, fingolimod, can harm the unborn baby and may cause birth defects.

During the Assembly of Delegates at the Oslo Congress, Professor Deuschl acknowledged Professor Hannah Cock’s longstanding tribute to EAN and her outstanding achievements in the Education Committee.